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T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphomas (T-LBL) are aggressive 
malignancies of thymocytes. The role of thymic microenvironmental cells and stromal factors in 
thymocyte malignant transformation and T-ALL development remains little explored. Here, using the 
TEL-JAK2 transgenic (TJ2-Tg) mouse model of T-ALL/LBL, which is driven by constitutive JAK/STAT 
signaling and characterized by the acquisition of Notch1 mutations, we sought to identify stromal cell 
alterations associated with thymic leukemogenesis. Immunofluorescence analyses showed that thymic 
lymphomas presented epithelial areas characterized by keratin 5 and keratin 8 exp ession, adjacently 
to epithelial-free areas negative for keratin expression. Both areas contained abundant laminin 




 (endothelial) and CD11c
+
 (dendritic) cells. 
Besides keratin 5, keratin-positive areas harbored medullary thymic epithelial cells (TEC) labeled by 
Ulex Europaeus agglutinin-1. By performing flow cytometry and RNA sequencing analyses of thymic 
lymphomas, we observed an enrichment in medullary TEC markers in detriment of cortical TEC 
markers. To assess whether TECs are important for T-ALL/LBL development, we generated TJ2-Tg 
mice heterozygous for the FoxN1 transcription factor nude null mutation (Foxn1
+/nu
). Strikingly, in TJ2-
Tg;Foxn1
+/nu
 compound mice both emergence of malignant cells in pre-leukemic thymi and overt T-
ALL onset were significantly delayed. Moreover, in transplantation assays leukemic cell expansion 
within the thymus of recipient Foxn1
+/nu
 mice was reduced as compared to control littermates. Since 
thymopoesis is largely normal in Foxn1
+/nu
 mice, these results indicate that FoxN1 haploinsufficiency in 
TECs has a more profound impact in thymic leukemogenesis. 
 
Summary 
Thymic epithelial cell composition is aberrant in mouse thymic lymphomas and reduced dosage of 





















T-cell acute lymphoblastic leukemia (T-ALL) and T lymphoblastic lymphomas (T-LBL) are aggressive 
thymocyte malignancies, as supported by similarities in the immunophenotypic, genotypic and 
transcriptomic profile of these leukemic cells and specific stages of intrathymic T-cell differentiation (1-
3). During intrathymic thymocyte differentiation, transformation events can lead to aberrant expression 
of oncogenic transcription factors that induce maturation arrest (4). Genetic abnormalities in T-ALL, 
including chromosomal translocations, point mutations, and deletions (4), typically result in the 
activation of signaling pathways frequently involved in cancer, most notably the PTEN/PI3K/AKT, 
Ras/MAPK and JAK/STAT pathways (5). Furthermore, one of the most common genetic alterations in 
T-ALL and T-LBL are NOTCH1-activating point mutations, present in more than 60% of cases (4,6). 
The same signaling pathways that are activated by intrinsic oncogenic mutations can also be activated 
by extrinsic signals provided by stromal cells in organs where T-ALL cells thrive. For example, despite 
the frequent presence of Notch1 mutations, T-ALL cells were shown to respond to and be maintained 
in vitro by NOTCH ligands, such as Delta-like ligand 1 and 4 (7-9).  
    Several extrinsic factors promoting T-ALL growth in vitro and in vivo were identified, including 
interleukin (IL)-7 (10-12), IL-18 (13), insulin-like growth factor (IGF)-1 (14), ICAM-1(15) and CXCL12 
(16,17). However, it remained unclear to what extent T-ALL development depends on signals from its 
native thymic microenvironment. In this regard, pioneering thymectomy experiments in mouse models 
have since long hinted that the thymic microenvironment was essential for T-cell acute 
leukemia/lymphoma (18,19). Subsequent reports indicated that stromal signals are important for 
leukemia maintenance, as the physical contact with thymic microenvironmental cells was shown to 
improve survival of co-cultured thymic-derived rodent primary leukemic T cells (20,21). Furthermore, 
histological and immunophenotypical studies showed that the thymic stroma undergoes profound 
alterations throughout thymic leukemogenesis in mice (22-24). Supportive of the role of the thymic 
microenvironment in human T-cell leukemogenesis, several T-ALL and T-LBL patients present thymic 
enlargement at diagnosis (3,25,26). Moreover, patient cells were shown to expand in alymphoid fetal 
thymic organ cultures from NOD/SCID mouse without supplementation of exogenous factors (27).  
    Thymopoiesis arises from incoming bone marrow progenitors that undergo T-cell differentiation 




















committed to the cell lineage at an immature phase characterized by the occurrence of genetic 
rearrangements of T-cell receptor (TCR) loci and identified by variable surface expression of CD25 
and CD44 proteins and absence of CD4 and CD8 expression (double negative or DN stage). Cells 
undergoing successful TCR β chain rearrangement express first CD8, and become immature single-
positive CD8 and then also CD4 and become so-called double-positive (DP) thymocytes. Depending 
on successful TCR α chain generation and negative and positive selection mediated by interactions 
with major histocompatibility complexes (MHC), thymocytes further differentiated into mature CD4 or 
CD8 single-positive (SP) T cells or regulatory T cells. Thymocyte development is achieved through a 
well-orchestrated bidirectional communication (so-called thymic crosstalk) between stromal cells and 
maturing thymocytes. These interactions trigger molecular changes in the thymic stromal 
microenvironment that are essential for thymocyte migration, differentiation and selection of functional 
mature T cells tolerant to self-antigens (28). The thymic microenvironment is composed of epithelial, 
mesenchymal, endothelial and hematopoietic cells (B lymphocytes, dendritic cells and macrophages). 
Thymic epithelial cells (TEC) are essential for the architecture of the embryonic and post-natal thymus, 
as demonstrated by genetic inactivation of the transcription factor FoxN1, an essential master 
regulator of TEC differentiation (29,30). The spatial organization of the thymus into compartments is 
associated with functionally different TEC subpopulations that are involved in the generation of 
successive stages of thymocyte development (31). Of note, cortical TEC (cTEC) are involved in T-cell 
lineage commitment and positive selection of thymocytes expressing functional T-cell receptor 
complexes, while medullary TEC (mTEC) are important for the generation of self-tolerant mature T 
cells. This function is mediated through MHC-mediated presentation of tissue-restricted self-antigens, 
which are essential for the negative selection of auto-reactive thymocytes and the generation of 
regulatory T cells (32).  
    The thymic molecular and cellular players involved in stromal support of thymocyte leukemogenesis 
have only recently began to be explored. Our group has reported that stromal cell inactivation of the 
RelB transcription factor and the TNF receptor superfamily member lymphotoxin-β receptor (LTβR), 
both components of the noncanonical NF-κB signaling pathway, delayed T-cell leukemia development 
in a transgenic mouse model expressing the TEL-JAK2 (also designated ETV6-JAK2) fusion protein in 
the lymphoid lineage (33,34). Recently, Triplett and colleagues (35) found in another T-ALL mouse 




















associated thymic dendritic cells (DCs) favored leukemic cell survival. Together, these data suggest 
that thymic microenvironmental cells participate in the development of T-cell leukemia. 
In the present study, we characterized the stromal cellular alterations in thymic leukemogenesis and 
found an increase in mTEC, but not cTEC molecular markers. More importantly, we found that 




















Materials and methods 
Mice 
Mice were bred and maintained at the CBMR/UAlg and IBMC/i3S barrier animal facilities (HEPA 
filtration of incoming air, differential pressure, and disinfection or sterilization of room equipment and 
supplies), under 12 h light/dark cycles, and with autoclaved food (4RF25 diet; Mucedola, Settimo 
Milanese, Italy) and water ad libitum. Microorganism screening (Charles River, L’Arbresle, France and 
Idexx Bioresearch, Ludwigsburg, Germany) detected opportunistic pathogens (Helicobacter spp., 
Pasteurella pneumotropica and murine norovirus) in the CBMR/UAlg and IBMC/i3S experimental 
rooms. The animal facilities and project were approved by the i3S ethics committee and Portuguese 
authorities (Direção-Geral de Agricultura e Veterinária). All experimental procedures were performed 
in accordance with European (Directive 2010/63/UE) and Portuguese (Decreto-Lei nº113/2013) 





/J) mice, which carry the nude (nu) null allele, were obtained 
from Instituto Gulbenkian de Ciência (Oeiras, Portugal). Upon breeding the two strains, always on the 
C57BL/6 genetic background, we obtained TJ2-Tg;Foxn1
+/nu
 but no viable TJ2-Tg nu/nu mice. 
Foxn1
+/nu 
mice were PCR genotyped using primers 5’-GGC CCA GCA GGC AGC CCA AG and 5’-
AGG GAT CTC CTC AAA GGC TTC CAG, followed by BsaJI PCR product digestion. For 
transplantation experiments, thymic-derived leukemic cells were prepared from diseased TJ2-Tg mice, 
suspended in phosphate-buffered saline (PBS) solution and injected into the tail vein of non-





 littermate mice (4 x 10
6
 cells per mouse). Mouse sex is indicated in figures. TJ2-Tg and 
leukemic cell recipient mice were monitored for leukemia development, and euthanized by CO2 
inhalation when manifesting signs of disease and reaching pre-defined endpoints (e.g. dyspnea, loss 
of activity and lymph node or abdomen enlargement). 
Flow Cytometry detection of hematopoietic cells 
Single-cell suspensions from lymphoid organs were prepared in PBS by tissue dissociation against a 
70 μm cell strainer (BD Biosciences, San Jose, CA, USA). Cells were collected by centrifugation and 




















Austria] and 10 mM NaN3) with fluorochrome-labeled antibodies. After washing with staining buffer, 
cells were analyzed in a FACS Calibur or C6 Accuri flow cytometer (BD Biosciences). Fluorescein 
isothiocyanate (FITC)-, R-phycoerythrin (PE)-, PE-cyanine 5 (PE-Cy5)-, or Allophycocyanin (APC)-
conjugated antibodies specific for CD90.2 (30-H12), CD11c (N418), SIRPα (P84), CD3ε (145-2C11), 
CD24 (M1/69), CD25 (PC61), CD4 (GK1.5), CD8 (53-6.7), and CD44 (IM7; BioLegend, San Diego, 
CA, USA) were used. Propidium iodide (P4170, Sigma-Aldrich, St. Louis, MO, USA) staining was used 
to gate viable cells for analysis. Analyses were performed on CellQuest (BD Biosciences) and FlowJo 
(FlowJo LLC, Ashland, OR, USA) software. 
Flow Cytometry detection of enzymatically dissociated thymic stromal cells 
Thymic stromal cells were isolated by enzymatic digestion as previously described (37). TECs were 
further enriched using a MACS-based CD45+ cell depletion kit (Miltenyi Biotec, Bergisch Gladbach, 
Germany). Before staining, cells were treated with Fc block (anti-CD16/CD32 antibodies TruStain FcX; 
Biolegend). Cell suspensions were stained as described (38) with PE-conjugated anti-CD80 (16-10A1) 
and anti-Ly51 (6C3), PerCP-Cy5.5-conjugated anti-CD45.2 (104), APC/eFluor660-conjugated anti-
CD80 (16-10A1), APC-eFluor780-conjugated anti-I-A/I-E (M5/114-15-2), eFluor660-conjugated anti-
CD11c (N418), eFluor450-conjugated anti-EpCAM (G8.8) (eBioscience, San Diego, CA), and BV785-
conjugated anti-Sca-1 (D7) (Biolegend). The binding of biotinylated Ulex europaeus agglutinin-1 (UEA-
1) (Vector Laboratories, Burlingame, CA) or anti-Ly51 (6C3) was revealed by PE-Cy7-conjugated 
streptavidin (eBioscience). Intracellular staining with APC/eFluor660-conjugated anti-Aire (5H12) 
antibody (eBioscience) was performed according to the supplier’s protocol. Flow cytometry data were 
acquired on a FACSCanto II and LSRFortessa, and analyzed on FlowJo software.  
Immunofluorescence 
Whole thymi were included and frozen in OCT compound (VWR, Radnor, PA, USA). Thymic 
cryosections of 6-10 µm were dried at 37ºC for 30 min before fixation with pre-cold acetone for 10 min 
at room temperature. Sections were re-hydrated in PBS, washed with PBSW solution (PBS with 0.1% 
Tween 20 [VWR]) and incubated with blocking solution (10% BSA [A9418, Sigma-Aldrich], 20% FBS 
in PBSW) for 1 h. Primary antibodies (Supplementary Table 1) were incubated overnight at 4ºC, 
washed with PBSW, followed by 1 h incubation with secondary antibodies (Supplementary Table 1) at 




















(Biotium, Fremont, CA, USA). Images were acquired with an Axio Imager Z2 fluorescence microscope 
(Carl Zeiss, Jena, Germany). Images were processed using open-source ImageJ and AxioVision (Carl 
Zeiss) software. Assembly of sequential images was performed using Pairwise Stitching in Fiji 
software. 
Quantitative RT-PCR analysis of whole and stromal cell-enriched thymic samples 
Stromal cell-enriched fractions were obtained by mechanically dissociating thymic tissue through a 70 
μm cell strainer in PBS and collecting the tissue retained in the mesh. Total RNA from whole thymus 
and stromal cell-enriched thymic samples was prepared using Trizol reagent (Life Technologies, 
Carlsbad, CA, USA) and phenol:chloroform extraction, according to the manufacturer’s instructions. 
Genomic DNA was removed from RNA samples with DNase I treatment (Thermo Fisher Scientific, 
Waltham, MA, USA). Reverse transcription was performed using the First Strand cDNA Synthesis Kit 
(Thermo Fisher Scientific) and oligo(dT)18 primers, according to the manufacturer’s instructions. For 
quantitative PCR, 2 μL of 1/20 diluted cDNA, SsoFast EvaGreen Supermix (Bio-Rad) and 300 nM of 
primers (Supplementary Table 2) in 20 μL were analyzed on a CFX 96 Real-time PCR detection 
system (Bio-Rad). The mean fold change in expression of the gene of interest was calculated in 
relation to expression of a reference gene (Hprt) by the comparative CT method (2
-ΔΔC(T)
 method). 
Genomic DNA extraction and Notch1 mutation detection 
Genomic DNA was extracted from TJ2-Tg leukemic cells using the GeneJET Genomic DNA 
purification kit (Thermo Fisher Scientific), following the manufacturer’s protocol. The exon 34 of 
Notch1 was PCR amplified as previously described (39), and purified PCR products were Sanger 
sequenced at GenCore/i3S and CCMAR (Faro, Portugal). 
Next Generation Sequencing 
Thymic stromal cell-enriched fractions from WT (5 male) and TJ2-Tg (1 female and 2 male) mice were 
obtained as described above and total RNA was extracted using the Direct-zol RNA Miniprep kit 
(Zymo Research). Next, mRNA was isolated using the NEBNext Poly(A) mRNA Magnetic Isolation 
Module (New England Biolabs, Ipswich, MA, USA), following the manufacturer’s instructions. The WT 
and TJ2-Tg mRNA samples were pooled and purified using the RNeasy MinElute Cleanup kit 




















Sequencing was performed on Ion Torrent PGM (Thermo Fisher Scientific) using Ion 316 Chip kits v2 
(Thermo Fisher Scientific) for the WT and TJ2-Tg pooled samples. Both FastQC and Prinseq indicated 
high sequence quality except for a residual adapter sequence in a subpopulation of reads. The latter 
was removed by Cutadapt software. Additionally, reads were trimmed when the corresponding Phred 
score fell below 25. Subsequently, reads were aligned to the full mouse genome (UCSC, version 
mm10) by the Torrent Mapping Alignment Program (TMAP). In total, 3,204,955 WT and 3,125,039 
TJ2-Tg reads were mapped to the mouse genome. Gene expression levels were obtained by HTseq-
count, and differential gene expression was assessed with Bioconductor package edgeR. 
Statistical analysis 
Graphs and statistical analyses were performed with GraphPad Prism software (La Jolla CA, USA). 
Statistical tests are indicated in the figure legends. Two-tailed t-tests were used to determine how 
significant were the differences between the means of two independent samples. Welch’s correction 





















TEL-JAK2 transgenic mouse thymic lymphomas present profound histological changes as compared 
to healthy thymi 
Transgenic expression of the TEL-JAK2 fusion protein in the lymphoid cell lineage (driven by the 
EμSRα enhancer/promoter) results in T-cell leukemia and lymphoma, affecting the thymus, spleen, 
lymph nodes and other organs (39). Signs of disease (labored breathing or abdominal or nodal 
enlargement) in EμSRα-TEL-JAK2 transgenic (TJ2-Tg) mice manifest at variable ages, usually 
between 8 and 20 weeks. No abnormalities in T-cell development are apparent in the initial weeks of 
life, but blind analysis of seemingly healthy 8-week-old TJ2-Tg mice revealed that in a subset of mice 
leukemic cells (identified by aberrant CD8 and CD25 co-expression) could be detected only in the 
thymus or in higher numbers in this organ than in other body locations (35). Further indicating that 
malignancy arises in the thymus, genetic blockade of T-cell development at the DP stage did not 
hamper leukemia/lymphoma development (40). Thymic lymphomas from TJ2-Tg mice often become 
10-20 times larger than age-matched control thymi and lose the typical thymic compartmentalization in 
cortex and medulla (36). To characterize in more detail the thymic microenvironmental changes during 
TJ2-Tg-induced leukemogenesis, we assessed the spatial distribution of several thymic stromal cells 
in diseased mice. Immunofluorescence analysis of large thymic lymphomas from overtly ill mice with 
antibodies against the keratin (Krt) 5 and Krt8 epithelial cell markers revealed large cellular regions 
lacking both Krt5- and Krt8-labeling, here designated as keratin-negative areas (KNA) (Supplementary 
Figure 1A and B). In contrast to the WT thymus, where medullary (Krt5-positive) and cortical (Krt8-
positive, Krt5-negative) regions were clearly spatially segregated (Figure 1, panels a1 and a2), keratin-
positive areas in thymic lymphomas displayed intermingled or overlapping Krt5 and Krt8 expression 
(Figure 1, panels a3 and a4, and Supplementary Figure 1C). Further spatial characterization based on 
Ulex Europaeus agglutinin-1 (UEA-1) binding and DEC205 protein expression, which respectively 
identify mTECs and cTECs (Figure 1, panels b1-b2, and c1-c2), showed that UEA-1
+
 mTECs were 
found within Krt5
+
 lymphoma areas (Figure 1, panels b3 and b4).. TJ2-Tg2 thymic lymphomas 
displayed a dense DEC205 staining in keratin-positive regions, notably stronger in areas with weaker 
Krt5 staining, suggesting that DEC205 labels residual cortical areas marked by ectopic Krt5 




















expressed by thymic DCs (40), DEC205
+
 cells in thymic lymphoma KNAs (Figure 1, panel c3 and c4), 
could indicate the presence of DCs. Indeed, CD11c immunolabeling, a more specific DC marker, 
showed increased proportions of DCs in thymic lymphomas distributed both within Krt5-positive and -
negative areas (Supplementary Figure 2).  
    As reported, fibroblast labeling by the ER-TR7 antibody was not restricted to any particular region of 
the WT thymus, but was more abundant in the thymic capsule, trabeculae, and lining of blood vessels 
(Figure 1, panels d1 and d2) (41). In TJ2-Tg thymic lymphomas, the pattern of ER-TR7 expression 
was similar in both keratin-positive and -negative areas, although a layer of ER-TR7
+
 cells marked the 
border between these two areas (Figure 1, panels d3 and d4, and Supplementary Figure 3A). Laminin 
labeling was similar to ER-TR7 labeling, in that it was present throughout the tumor tissue, irrespective 
of keratin labeling, and marking the boundary between keratin-positive and -negative areas (Figure 1, 
panels e3 and e4). The CD31 marker, labeling endothelial cells, was also present throughout the 
thymic lymphoma tissue (Figure 1, panels f3 and f4). Double immunofluorescence analyses showed 
that all CD31
+
 lymphoma blood vessels were surrounded by laminin (Supplementary Figure 3B), which 
is normally a component of vascular basement membranes (42).  
    While F4/80
+
 macrophages were scattered in normal thymic tissue (Figure 1, panels g1 and g2), 
these cells were also distributed throughout thymic lymphomas, albeit more abundantly in keratin-
positive areas (Figure 1, panels g3 and g4). Finally, we also analyzed the distribution pattern of the 
integrin-binding ICAM-1 adhesion molecule. As previously reported (43,44), ICAM-1 was detected 
both in the thymus cortex and medulla, although more prominently in the latter (Figure 1, panel h1). In 
TJ2-Tg thymic lymphomas, ICAM-1 expression was more prevalent in areas of stronger Krt5 labeling 
(Figure 1, panels h3 and h4), often co-localizing at the cellular level (Supplementary Figure 3C).  
    The immunohistological data indicate that the composition of TECs is altered in thymic lymphomas, 
with a predominance for mTEC marker expression. To evaluate TEC alterations through another 
method, we performed gene expression analysis of whole thymic lymphomas. Quantitative PCR 
revealed a significant decrease in Krt5 and Krt8 transcripts within lymphomas as compared to normal 
whole thymi, confirming the notion that the proportion of thymic epithelial cells was reduced 
(Supplementary Figure 4). Furthermore, the ratio of Krt5/Krt8 mRNA levels was significantly higher in 
lymphomas than in normal thymi (Supplementary Figure 4), thus supporting the notion that mTEC 




















    Since the aforementioned results were based on analysis of large thymic lymphomas (from overtly 
ill TJ2-Tg mice), weighing from 500 to 1400 mg, we also assessed by immunofluorescence the extent 
of stromal cell alterations in smaller lymphomas, i.e. above the weight of a normal adult thymi 
(between 50 and 100 mg) but below 400 mg (Figure 2A). These analyses led to two main findings. 
First, Krt5 labeling was expanded in relation to Krt8 labeling, with concomitant loss of the normal 
cortico-medullary compartmentalization (Figure 2A, second row panels). Second, the extension of 
KNAs, which contained abundant ER-TR7
+
 fibroblasts, increased with lymphoma size (Figure 2A, third 
row panels). Since an evident expansion of Krt5
+
 in relation to Krt8
+
 areas was recurrently detected in 
TJ2-Tg thymic lymphomas, we have also immunostained thymic lymphomas for the UEA-1 medullary 
marker, and this led to a similar staining pattern as that of Krt5 (Figure 2A, bottom panels). These 




 TECs expand in detriment of Krt8
+
 TECs during lymphoma formation. 
Flow cytometry detection of thymic lymphoma-derived stromal cells  
To further characterize the TEC subpopulations in TJ2-Tg thymic lymphomagenesis, we compared the 

















) in aged-matched WT mice and TJ2-Tg mice with or without leukemic cells. Confirming the 
notion that cTECs decline with leukemogenesis, the proportion of cTECs was generally lower in TJ2-
Tg thymic lymphomas than in WT or TJ2-Tg thymi without leukemic cells (Figure 3, compare TJ2-Tg 









) was dominant in thymic lymphomas 
(Figure 3). These data indicate that thymic leukemogenesis is accompanied by loss of cTECs relative 
to mTECs. 
Global gene expression analysis reveals alterations in thymic stromal cell composition early in 
leukemogenesis 
To gain further insights into the nature of the stromal cell alterations in thymic leukemogenesis, we 
used an unbiased genome-wide transcriptomic approach. Because thymocytes represent the 
overwhelming majority of thymic cells and we aimed to obtain transcriptomic data from stromal 
populations, we depleted the former from thymic samples by mechanical disruption of thymic 
fragments, a procedure that mostly liberates hematopoietic cells. Since standard thymus enzymatic 




















RNA from non-digested stromal cell-enriched thymic fractions (see Materials and methods section). 
This fractionation method maintained a diverse set of stromal cells (including TECs, DCs and 
mesenchymal cells) and led to enrichment of thymic stromal cell genes and depletion (but not 
exclusion) of thymocyte-specific genes (Supplementary Figure 5). We compared WT with TJ2-Tg (8- 
to 10-week-old) mice with no external signs of disease but presenting incipient leukemogenesis, 





 leukemic cells within the thymocyte population (not shown). Pooled RNA samples were 
subjected to high-throughput sequencing, and bioinformatic analyses disclosed 640 differentially 
expressed genes (DEGs), 199 upregulated in WT thymi (Supplementary Table 3) and 441 upregulated 
in TJ2-Tg thymi (Supplementary Table 4). As expected from the crude stromal fractionation, several 
genes differentially expressed between WT and TJ2-Tg samples most likely derive from T lineage 
cells (e.g., Ptcra, Rag1, Rag2, Dntt, Themis, etc.). Nevertheless, many up- or downregulated genes 
were well-characterized stromal cell markers (e.g. Ccl25, Vim, Lepr, S100a4, Zbtb46, Xcl1, etc.). To 
know if the identified DEGs reflect imbalanced representation of distinct thymic stromal cell 
proportions, we investigated whether they contained lineage-restricted genes expressed in particular 
thymic stromal cell subsets, as previously identified by Ki and colleagues (47). Interestingly, of 116 
cTEC-specific genes, 17 were upregulated in WT compared to TJ2-Tg thymi whereas none was 
upregulated in TJ2-Tg compared to WT thymi (Figure 2B and C, and Supplementary Table 5). These 
findings confirm that cTEC markers are downregulated during lymphomagenesis. In contrast, mTEC-
specific genes were not significantly enriched in either WT or TJ2-Tg samples. In addition, we 
observed that several genes specific of Sirpα
+
 DCs were upregulated in TJ2-Tg but not WT thymi 
(Figure 2B and C and Supplementary Table 5). These data indicate that thymic leukemogenesis in 
TJ2-Tg mice is accompanied by alterations in TEC subset proportions and an increase in DCs.  
Foxn1 haploinsufficiency delays the onset of TEL-JAK2-induced leukemia 
To assess whether TECs play a role in thymic leukemogenesis, we generated TJ2-Tg mice lacking 
one Foxn1 allele, a gene shown to influence TEC development and maintenance in a dose-dependent 
manner (29). Mice carrying the Foxn1 nude mutation in heterozygosity presented normal proportions 
of thymocyte developmental stages (as defined by CD4, CD8, CD25 and CD44 expression), including 
































Figure 6A and B), which are the main cellular targets for TJ2-Tg malignant transformation (48). It was 
reported that Foxn1
+/nu
 mice younger than five weeks of age present lower thymic weight than WT 
controls (29,49,50). Since TJ2-Tg leukemia arises during adulthood, i.e. between 6 and 20 weeks, we 
determined the thymic weight in older mice. Although 8 or 20 week-old Foxn1
+/nu
 mice presented 
slightly smaller thymi than Foxn1
+/+
 littermates (1.1-1.3-fold difference) (Supplementary Figure 6C), no 
statistically significant differences in thymic weight were found when considering females alone or 





 TJ2-Tg mouse cohorts showed that the onset of leukemia was delayed in TJ2-
Tg mice with Foxn1 haploinsufficiency (Figure 4A). Survival analysis of each sex separately revealed 
that Foxn1 haploinsufficiency delayed leukemia onset in both settings (Figure 4B). Despite the 
different survival rates of the two cohorts, no significant differences were observed regarding end-
stage tumor load (Figure 4C). Moreover, overtly diseased TJ2-Tg;Foxn1
+/nu
 mice presented leukemic 
cells expressing characteristic markers (CD3, CD4, CD8, CD24 and CD25) and thymic lymphomas 
displayed KNAs and areas of overlapping Krt5 and Krt8 staining as control Foxn1
+/+
 lymphomas 
(Supplementary Figure 7). Like in other T-ALL mouse models, TJ2-Tg leukemic cells were found to 
acquire activating frameshift mutations in the PEST domain-encoding Notch1 exon 34 (>65% 
incidence) (Supplementary Table 6). Notch1 PEST domain heterozygous mutations, identified by the 
simultaneous detection of WT and mutated sequences (Supplementary Figure 8), occurred with 
similar frequency, in leukemic cells from both Foxn1 haploinsufficient and control TJ2-Tg mice (Table 
1). These mutations consisted of deletions and/or insertions, often affecting the previously reported 
exon 34 hotspots (codons 2361 and 2398/99) (51,52) and leading to premature stop codons and 
predicted loss of the C-terminal PEST domain (Table 1). Together, these data indicate that FoxN1 
haploinsufficiency delayed leukemogenesis without influencing the major disease characteristics. 
    To investigate whether thymic defects caused by Foxn1 haploinsufficiency impacted on the earliest 
detectable phases of leukemogenesis, we monitored the emergence of leukemic cells in young (8 




 leukemic cells within total 
thymocytes, (Figure 4D). At this age, leukemic cells can be detected in TJ2-Tg thymi without 










 leukemic cells (Figure 4E). However, thymi from TJ2-Tg;Foxn1
+/nu
























 cells than TJ2-Tg;Foxn1
+/+
 thymi (7.8-fold difference; 




 cells were 
barely detectable in the blood, bone marrow and spleen of mice of both Foxn1 genotypes (Figure 4F 
and not shown). These findings indicate that leukemic cell emergence in the thymus is delayed when 
Foxn1 gene dose is reduced in TEC. Although Foxn1 haploinsufficiency leads to a mild decrease in 
thymic size, which could contribute to the observed delayed leukemogenesis, the above-presented 
data suggest that reduction in FoxN1 expression levels in TECs has a more marked impact on 
leukemogenesis than on thymocyte generation and differentiation. 
The Foxn1-dependent thymic microenvironment facilitates leukemic cell expansion 
To determine the role of the Foxn1-dependent microenvironment in leukemia maintenance, leukemic 





 littermate controls (Figure 5A). When manifesting signs of disease, recipient mice were 
killed for macroscopic and flow cytometry analyses. Although the spleen and liver were the most 




 leukemic cells (Figure 
5B). Two independent experiments using either male or female recipients were performed and each 
revealed a trend towards lower tumor load in Foxn1
+/nu
 thymi (Figure 5C). Following data normalization 
and pooling, we found that Foxn1
+/nu
 mice displayed statistically significant lower thymic weight than 
Foxn1
+/+ 
littermates (Figure 5D). In contrast, the relative splenic and hepatic tumor load was not 
influenced by Foxn1 genotype (Figure 5D). These results thus indicate that Foxn1 expression in TECs 





















The malignant transformation of mouse or human thymocytes is triggered by the deregulation of key 
cellular mechanisms due to both cell-intrinsic genetic alterations and microenvironmental stimulation 
(53,54). Here, using a mouse model of JAK kinase-driven and Notch1-mutated T-ALL, we identified 
several microenvironmental cellular alterations associated with thymic lymphoma development and 
progression. These included shifts in expression of TEC markers, with loss of cortical and increase of 
medullary epithelial cell markers, together with increased proportions of fibroblasts, DCs and 
endothelial cells. Highlighting a role for TECs, we found that reducing the genetic dose of FoxN1, an 
essential TEC transcription factor in TEC differentiation, delayed thymic leukemogenesis.  
    Diseased TJ2-Tg mice present large thymic lymphomas with loss of cortico-medullary demarcation 
and frequent disruption of the thymic capsule (33,36). By performing immunohistological analyses 
against thymic keratin proteins, we observed that TJ2-Tg mouse thymic lymphomas developed 
conspicuous areas without keratin expression, which were more extensive in larger lymphomas. 
Similar observations were reported in thymic lymphomas from other mouse models (22,35). In TJ2-Tg 
mice, KNAs included fibroblasts and laminin-containing extracellular matrix, suggesting that leukemic 
cells first invade the capsular connective tissue before expanding outwardly, thus generating 
lymphomatous KNAs. By studying spontaneous thymic lymphomas of different sizes, we found that 
the normal cortico-medullary demarcation was lost. This phenomenon was accompanied by a strong 
reduction in cortical (Krt8-positive, Krt5-negative) areas, which is in agreement with earlier reports of 
cortical atrophy and m dullary expansion at pre-leukemic stages of viral-induced murine thymic 
lymphoma (23,24,55-57). Our data thus support the concept that upon emergence of leukemic cells in 
the thymus, these disseminate throughout all thymic compartments, impacting on TEC differentiation 
and/or distribution, before invading the thymic capsule and undergoing further expansion.  
    FoxN1 is a pivotal transcription factor for thymus and skin epithelial cell differentiation in rodents 
and humans (58). However, its role in cancer is less understood. Previous evidence indicated that 
FoxN1 suppresses the transition from benign to malignant keratinocyte lesions (59). Another report 
supporting a tumor-suppressive role for Foxn1 showed that its haploinsufficiency accelerated thymic 
leukemogenesis in the endogenous retrovirus-expressing AKR murine strain (60). In contrast with 




















JAK2-induced leukemia/lymphoma and the thymic expansion of leukemic cells in recipient mice. Since 
leukemogenesis in TJ2-Tg mice is initiated in the thymus (34,48) and TECs are the only thymic cells 
expressing Foxn1, we conclude that the delayed leukemogenesis in heterozygotes is caused by 
FoxN1-mediated defects in TECs. Despite the observed delay in leukemia onset, all TJ2-Tg;Foxn1
+/nu
 
mice succumbed to disease with similar pathological and molecular features as Foxn1
+/+
 controls. 
These findings suggest that TJ2-Tg leukemogenesis is not profoundly altered by Foxn1 
haploinsufficiency, but that it takes longer to develop, at initiation and/or progression. The finding that 
pre-leukemic TJ2-Tg;Foxn1
+/nu




 thymic cells than TJ2-
Tg;Foxn1
+/+
 mice suggests that Foxn1 haploinsufficiency in TECs impacts disease development very 
early on. 
    Foxn1 haploinsufficiency was shown to cause a moderate reduction in thymic weight of mice under 
5 weeks of different outbred and inbred strains (29,49,50). Young adult Foxn1
+/nu
 mice (8 and 20 
weeks of age) displayed a mild reduction in thymic weight, which was less evident considering 
females alone or older mice, but no defects in Foxn1
+/nu
 thymocyte maturation were apparent. Further 
supporting the notion that delayed leukemogenesis caused by Foxn1 haploinsufficiency is not due to a 
mere decrease in thymocyte cellularity, the decrease in adult thymic weight at 8 weeks of age caused 
by loss of one Foxn1 allele was much less pronounced (1.3-fold) relatively to the delay in both 
emergence of thymic leukemic cells at 8 weeks (7.8-fold) and leukemia-related TJ2-Tg mouse death 
(2.2-fold higher mortality rate at 20 weeks of age). Although a putative role for reduced thymocyte 
cellularity cannot be formally excluded, our data indicate that the delayed thymic leukemogenesis 
caused by Foxn1 haploinsufficiency results from an as yet unidentified cellular mechanism acting 
specifically on leukemic cell propagation but not on thymocyte development.  
    Although the FoxN1-mediated mechanism fostering leukemogenesis remains unclear, it is possible 
that leukemic cell development is more sensitive than thymocyte development to changes in 
expression of specific FoxN1 target genes. In this line, we observed that Foxn1 haploinsufficiency was 
associated with a mild reduction in Ccl25 thymic expression (not shown), a well-established FoxN1 
target gene (30,61) and a potential T-ALL growth factor (62). Future studies should address whether 
this or other FoxN1 target genes (e.g. Dll4 and Cxcl12) play direct roles in thymic leukemogenesis. 
Alternatively, FoxN1 could impinge on leukemogenesis indirectly through changes in functional 




















accompanied by a disorganization in TEC marker expression, it is possible that Foxn1
+/nu
-associated 
TEC differentiation defects underlie the delayed leukemia onset in TJ2-Tg;Foxn1
+/nu
 mice. In addition, 
TECs were shown to regulate both thymic vascularization (63,64) and thymic DC development, 
differentiation and recruitment (65-67). Whether Foxn1 haploinsufficiency in TECs is linked to vascular 
or DC defects warrants further investigation.  
    It was previously shown that RelB and LTβR proteins, both expressed in mTEC and other thymic 
stromal cells, contribute to leukemogenesis (33,34). Additionally, these proteins are essential for 
thymic medulla development and maintenance, as shown by the impaired medullary compartment of 
the respective knock-out mice (68,69). The notion that RelB, LTβR and FoxN1 hinder leukemogenesis 
and that all are expressed in mTECs suggest that these or other medullary cell types are involved in 
thymic leukemogenesis.  
    Using a panel of thymic cell markers, we detected major organizational alterations involving several 
thymic stromal cell types in smaller and larger TJ2-induced lymphomas. Most notably, we observed 
increased expression of CD31 and ER-TR7, markers for endothelial cells and thymic fibroblasts, 
respectively, suggesting that angiogenesis, fibroblast proliferation and accrued ECM deposition, which 
are often associated with cancer (70) may favor thymic lymphomagenesis, especially at the most 
advanced stages. We have also found expression of markers for macrophages (F4/80) and DCs 
(CD11c and DEC205) in lymphomas. Macrophages have been identified in mouse thymic lymphomas 
(23,56,71), and recent studies indicate that lymphoma-associated macrophages stimulate T-ALL 
proliferation in vitro (72). Thus, the potential involvement of tumor-associated macrophages in T-cell 
leukemogenesis merits further investigation. DCs are usually associated with an anti-tumoral role via 
their function in adaptive immunity as tumor antigen-presenting cells (73). However, it was recently 
shown that DCs favored survival or proliferation of B and T leukemic cells (35,74). More specifically, 
Triplett et al. (35) reported that thymic lymphoma-derived DCs (most notably Sirpα-positive DCs) 
promoted leukemic T cell survival through IGF-1 and PDGF (platelet-derived growth factor) secretion. 
An increased proportion of DCs and increased expression of Sirpα
+
 DC genes was found in the 
stroma of TJ2-Tg thymic lymphomas, so studies determining whether DCs are involved in TJ2 
leukemogenesis are warranted.  
    Together, our findings demonstrate that the thymic microenvironment in general and TECs 




















molecular signals produced by stromal cells will not only shed further light on the mechanisms 






















Supplementary Figures 1 through 8 and Supplementary Tables 1 through 6 can be found at 
http://carcin.oxfordjournals.org/  
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LEGENDS TO THE FIGURES 
Fig. 1. Characterization of the thymic stromal cellular alterations in advanced stage thymic lymphomas 
from TJ2-Tg mice. Double immunofluorescence staining of a WT thymus (panels numbered 1 and 2) 
and two representative TJ2-Tg thymic lymphomas (mouse nº 341, panels numbered 3 and 4, except 
panels b3 and b4; mouse nº 128, panels b3 and b4) out of at least three analyzed, with antibodies 
against the indicated markers. The higher magnification panels (numbered 2 and 4) depict a thymic 
region encompassing both medulla and cortex (panels a2-g2) and keratin-positive and negative 
boundaries (panels a4 to h4). For panels a1, b1, a3 and b3 DAPI staining (blue) is shown. Scale bars: 
200 μm (panels numbered 1 and 3), 400 μm (panels numbered 2 and 4). When present, dashed-line 
rectangles represent the magnified area.  
Fig. 2. Smaller TJ2-Tg lymphomas present thymic medullary expansion and cortical reduction. (A) 
Cryosections from TJ2-Tg thymic lymphomas of the indicated weights were immunostained for Krt5, 
Krt8, and UEA-1 thymic epithelial markers and the ER-TR7 fibroblast marker. Asterisks indicate KNAs; 
dashed-line rectangles represent area magnified in the inset panel. Scale bars: 200 μm (main panels), 
100 μm (inset panels). (B) Venn diagrams displaying the overlap between gene sets characteristic for 
cortical thymic epithelial cells (cTEC), me ullary thymic epithelial cells (mTEChi and mTEClo), 
dendritic cells (DC and DCS, negative and positive for Sirpα, respectively) and fibroblasts from the Ki 
et al. study (47) and upregulated genes in WT versus TJ2-Tg (T-ALL) thymic stromal fractions. (C) For 
each stromal cell subset, the number and percentage of genes differentially expressed between WT 
versus TJ2-Tg (T-ALL) thymic stromal fractions is given. P values determined by two-tailed Fisher’s 
exact test. 
Fig. 3. TEL-JAK2-induced thymic lymphomas present an increased proportion of medullary relative to 
cortical thymic epithelial cells. Flow cytometry analysis of thymocyte suspensions (most left panels) 
and thymic stromal cells obtained from enzymatically digested tissue (all other panels) of four 
representative mice, a wild-type mouse, a TJ2-Tg mouse without leukemic cells (nº32) and two TJ2-Tg 
mice presenting thymic leukemic cells (nº31 and 29). CD4 and CD8 staining identified normal (WT and 
nº32) and aberrant (nº31 and 29) thymocyte populations. Gating on EpCAM
+
 cells, i.e. TECs, allowed 
identification of mTECs (UEA-1
+





































) subsets. Specialized mature Aire
+
 mTECs,  detected by Aire and MHCII co-
expression, were also analyzed. Values represent percentage of cells within each quadrant or region. 
Fig. 4. Foxn1 haploinsufficiency delays TEL-JAK2-induced leukemogenesis. (A) Kaplan-Meier 




 mice, with median 
survivals of 16 and 23 weeks, respectively (log-rank test, P value ≤ 0.0001). Hazard ratio of 2.93, with 
95% CI of 1.90 to 4.51. Both groups of mice include an equal ratio (1:1.6) of females to males. (B) 
Kaplan-Meier leukemia-free survival curves for cohorts of female or male mice. The median survival of 




, respectively (log-rank test, P 





respectively (log-rank test, P value ≤ 0.0001). (C) Weights of thymus, spleen, lymph nodes and liver 




 mice. (D) Thymocyte flow 
cytometry analysis of three representative 8-week-old TJ2-Tg mice without external signs of disease 





 cells (bottom panels). Percentage of cells in each region is shown. (E) Thymic weight 




 littermate mice (top panel) and its correlation with 









leukemic cells in thymic, splenic, and blood cell suspensions from same mice as in (E). (C, E, F) Data 
are presented with mean ± SEM. P values determined by two-tailed, unpaired t-test with Welch’s 
correction (**, P ≤ 0.01; ns, non-significant). 
Fig. 5. Foxn1 haploinsufficiency impairs leukemic cell expansion in recipient mouse thymi. (A) 
Transplantation experiment design. (B) Flow cytometry detection of CD25
+
 leukemic cells in thymic 
cell suspensions of recipient littermate mice with the indicated genotype. Data shown is representative 
of one of two independent experiments performed with leukemic cells originated from two different 
TJ2-Tg diseased mice. (C) Thymic weights of recipient mice from two independent experiments, one 
with male and another with female recipients. (D) Relative organ weights from recipient mice of 
transplantation experiments shown in (C) pooled after normalization based on the average weight of 
the WT (Foxn1
+/+
) animals in each experiment. (B-D) Data are presented with mean ± SEM; P value 





















Table 1. Exon 34 Notch1 mutations in TJ2-Tg-induced mouse leukemia samples 













23 M 10 mut 2362 Ins C 
24 M 13 wt - - 
27 F 10 mut 2361 Del G, Ins CC 
41 F 12 wt - - 
73 F 13 mut 2399 Ins GGGGGGG 
90 M 16 mut 2361 Del C, Ins AA 
263 M 19 mut 2431 Ins A 
311 F 12 mut 2377 Ins C 
599 M 31 wt - - 
613 F 28 wt - - 




10 F 15 wt - - 
12 F 15 mut 2361 Ins TCACGGC 
17 M 25 wt - - 
26 M 16 wt - - 
30 F 14 mut 2361 Ins CA 
33 M 18 wt - - 
37 F 54 wt - - 
38 F 16 wt - - 
39 F 20 wt - - 
45 M 13 wt - - 
47 M 60 wt - - 
52 M 13 wt - - 
58 M 18 mut 2398 Del G, Ins CCCGCA 




















66 M 13 mut 2361 Del G, Ins CC 
72 F 8 wt - - 
88 M 9 wt - - 
96 F 30 wt - - 
97 F 12 wt - - 
140 F 13 mut 2361 Del C, ins GT 
292 F 15 mut 2398 Ins TTCC 
579 F 36 mut 2361 Del G, Ins CC 
580 M 41 wt - - 
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